Proactive Investors - Run By Investors For Investors

WideCells expands its reach to Spain

"The Spanish cord blood and stem cell storage market is one of the most established in Europe and accordingly is a highly prospective region for us,” said chief executive João Andrade
stem cell
The company is a specialist in the storage of stems cells from the umbilical cord, which could provide a potentially life-saving treatment for 82 blood-borne diseases

WideCells Group PLC announced it will launch its stem cell healthcare insurance plan in Spain following the product’s debut here in the UK and alongside its imminent roll-out in Brazil.

The local agent for the CellPlan, which costs £170 a year, will be a company called Stem Cell Banco Celulas Madre, a provider of stem cell storage services. Under the re-seller model, the tie-up should generate £50 per sale (after commissions and reinsurance costs).

READ: WideCells ready to ink deal that expands its reach to the Middle East, Africa and Asia-Pacific

In the same stock market announcement, WideCells confirmed its CellPlan e-commerce platform is now “fully live” in the UK. It is expected to be available in Spain by the end of the year.

Established market

"The Spanish cord blood and stem cell storage market is one of the most established in Europe and accordingly is a highly prospective region for us,” said chief executive João Andrade.

“Having successfully launched our CellPlan product in the UK, and with sales due to commence in Brazil in the near term, we now have an established framework and roll-out model which enables us to target new geographies quickly and with relatively low cost.”

On Wednesday, the company inked a deal that will take it and its stem cell services into the Middle East, Africa and Asia-Pacific regions.

Storage expert

The company is a specialist in the storage of stems cells from the umbilical cord, which could provide a potentially life-saving treatment for 82 blood-borne diseases, including leukaemia and lymphoma. The storage and research operation is the core WideCells business.

READ: WideCells Group ready for UK stem cell storage licence

It has also developed the aforementioned insurance plan that will allow people to pay for treatments using the umbilical material, which already now making money for the firm.

Alongside that it is creating a software platform that both educates and keeps medical professionals and parents up to date on new treatments and developments.

View full WDC profile View Profile

WideCells Group Timeline

Related Articles

Nemaura Medical Inc CEO Dr Faz Chowdhury
November 05 2018
The medtech company is eying explosive growth with sugarBEAT, on the cusp of launching in the UK, followed by the rest of Europe in 2018
myLotus testing kit
October 31 2018
The launch at the Fertility Show in London at the start of November is the first step in a switch in focus brought about by new executive chairman Matthew Walls
PT exercises
December 19 2018
The Californian company is a bet on an industry that is in need of transformation

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use